Day One Biopharmaceuticals shares surged over 65% in pre-market trading after pharma firm Servier agreed to acquire the company for $21.50 per share in cash, valuing the deal at about $2.5 billion. The acquisition aims to strengthen Servier's oncology pipeline, particularly in treatments for paediatric low-grade glioma and other cancers.